NCT02771860View on ClinicalTrials.gov

RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 26, 2019

Study Completion Date

April 28, 2021

Conditions
Hand Osteoarthritis
Interventions
DRUG

denosumab

60mg sc

DRUG

Placebo

identical syringe

DIETARY_SUPPLEMENT

Calcium/Vit D supplementation

Daily dosage Calcium 1000mg / Vit D 880 IU

Trial Locations (1)

9000

UZ Ghent, Ghent

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University Hospital, Ghent

OTHER

NCT02771860 - RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints | Biotech Hunter | Biotech Hunter